Otonomy, Inc.

135 articles with Otonomy, Inc.

• Otonomy to Participate in the H.C. Wainwright BioConnect 2021 Virtual Conference

  1/5/2021

  Otonomy, Inc. announced that management is scheduled to participate in a fireside chat at the virtual H.C. Wainwright BioConnect 2021 Conference to be held January 11-14, 2021.

• 

  Clinical Catch-Up: December 14-18

  12/21/2020

  Many companies appear to be getting their clinical trial news updated ahead of the holidays. Here’s a look.

• Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-413 in Patients with Hearing Loss

  12/17/2020

  OTO-413 demonstrated a higher proportion of responders than placebo based on multiple speech-in-noise hearing tests A single intratympanic injection of OTO-413 was well-tolerated Otonomy intends to continue clinical development of OTO-413 Management will review results during a conference call today at 8 a.m. ET

• 

  Clinical Catch-Up: November 30-December 4

  12/7/2020

  It was a moderately busy week for clinical trial news, with some important reports coming out about COVID-19 vaccines. Here’s a look.

• Otonomy Provides Update on OTIVIDEX® and OTO-313 Programs

  11/30/2020

  Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided updates regarding the statistical analysis plan for the ongoing Phase 3 trial of OTIVIDEX in Ménière’s disease, and outlined plans for a Phase 2 trial of OTO-313 in tinnitus.

• Otonomy to Participate in Two Upcoming Investor Conferences - Nov 16, 2020

  11/16/2020

  Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, announced that management is scheduled to participate in two upcoming virtual investor conferences.

• Otonomy Reports Third Quarter 2020 Financial Results and Provides Corporate Update

  11/4/2020

  Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported financial results for the quarter ended September 30, 2020 and provided an update on its product pipeline and corporate activities.

• Otonomy to Report Third Quarter 2020 Financial Results and Provide Corporate Update

  10/28/2020

  Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the third quarter of 2020 and provide a corporate update at 4:30 p.m. ET on November 4, 2020. The live call may be accessed by dialing (877) 305-6769 for domestic callers and (678) 562-4239 for international callers with conference ID code number: 5179918. A live web

• 

  Clinical Catch-Up: September 28-October 2

  10/5/2020

  Biopharma companies wrapped up September and headed into October with plenty of clinical trial news. Here’s a look.

• Otonomy Completes Patient Enrollment for Phase 3 Trial of OTIVIDEX® in Ménière’s Disease

  10/2/2020

  Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the completion of patient enrollment in the Phase 3 clinical trial of OTIVIDEX in Ménière’s disease. A total of 149 patients have been enrolled in the trial, exceeding the target of 142 patients. Following randomization to treatment with a single intratympanic injection of OTIVIDEX or placebo, patients ar

• Otonomy to Participate in Four Upcoming Investor Conferences

  9/2/2020

  Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that management is scheduled to participate in four upcoming virtual investor conferences. Citi’s 15 th Annual BioPharma Virtual Conference on September 9-10, 2020: 1 on 1 investor meetings.   H.C. Wainwright 22nd Annual Global Investment Conference: presentation on September 14, 2020 at 12 p.m. ET (

• Otonomy Reports Second Quarter 2020 Financial Results and Provides Corporate Update

  8/4/2020

  Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported financial results for the quarter ended June 30, 2020 and provided an update on its product pipeline and corporate activities

• Otonomy Announces Exclusive License Agreement with Kyorin for Novel Compound in OTO-6XX Hearing Loss ProgramCompound has potential to benefit patients with severe hearing loss

  8/3/2020

  Otonomy, Inc. announced an exclusive license agreement with KYORIN Pharmaceutical Co., Ltd. that provides Otonomy with exclusive worldwide rights to develop, manufacture and commercialize a novel compound for the treatment of sensorineural hearing loss.

• Otonomy to Report Second Quarter 2020 Financial Results and Provide Corporate UpdateWebcast and Conference Call to be Held at 5 p.m. EDT on August 4, 2020

  7/28/2020

  Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the second quarter of 2020 and provide a corporate update at 5 p.m. EDT on August 4, 2020.

• Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

  7/13/2020

  Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the closing of its previously announced underwritten public offering of 17,275,000 shares of its common stock, which includes the underwriters' full exercise of their option to purchase additional shares and pre-funded

• 

  Clinical Catch-Up: July 6-10

  7/13/2020

  Everybody seems to be back to work after the U.S. 4th of July holiday. Here’s a look at last week’s clinical trial updates.

• Otonomy Announces Pricing of $60.1 Million Public Offering - July 09, 2020

  7/9/2020

  Otonomy, Inc. announced the pricing of an underwritten public offering of 14,500,000 shares of its common stock at a price to the public of $3.25 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 4,000,000 shares of its common stock at a purchase price of $3.249 per each pre-funded warrant...

• Otonomy Announces Proposed Public Offering - July 08, 2020

  7/8/2020

  Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, announced that it has commenced an underwritten public offering of its common stock.

• Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-313 in Patients with Tinnitus

  7/6/2020

  Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced positive top-line results from the Phase 1/2 clinical trial of OTO-313 in patients with persistent tinnitus of at least moderate severity.

• Otonomy Provides Update on OTIVIDEX® ProgramManagement will review the OTIVIDEX statistical analysis plan update together with the positive top-line OTO-313 Phase 1/2 trial results during a conference call today at 4:30 p.m. ET

  7/6/2020

  Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, provided an update on the statistical analysis plan related to the ongoing Phase 3 clinical trial of OTIVIDEX in Ménière’s disease.